MedTrace Logo

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

NCT05523440 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2025-03-28

No results posted yet for this study

Summary

The purpose of this research study is to test the proportion of tumor response to the combination treatment with niraparib and bevacizumab and see what effects (good and bad) this combination treatment has on patients with recurrent endometrial or ovarian cancer with ARID1A mutation.

Conditions

  • Recurrent Endometrial Carcinoma
  • Recurrent Ovarian Carcinoma
  • ARID1A Gene Mutation

Interventions

DRUG

Bevacizumab

Bevacizumab infusion.

DRUG

Niraparib

Niraparib oral capsule.

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University of Virginia

    collaborator OTHER

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Lauren Dockery, MD · Stephenson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-15
Primary Completion
2025-01-08
Completion
2025-01-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05523440 on ClinicalTrials.gov